Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y287

UPID:
ITM2B_HUMAN

ALTERNATIVE NAMES:
Immature BRI2; Protein E25B; Transmembrane protein BRI

ALTERNATIVE UPACC:
Q9Y287; Q5W0A3; Q96B24; Q9NYH1

BACKGROUND:
The protein Integral membrane protein 2B, with aliases such as Immature BRI2 and Protein E25B, is instrumental in regulating amyloid-beta A4 precursor protein (APP) processing. It significantly reduces the secretion of amyloid-beta, thereby playing a key role in neuronal health and preventing the aggregation of toxic oligomers.

THERAPEUTIC SIGNIFICANCE:
Given ITM2B's critical function in inhibiting amyloid-beta peptide aggregation and its association with conditions like Retinal dystrophy with inner retinal dysfunction, understanding its role could open doors to potential therapeutic strategies. Targeting ITM2B could lead to novel treatments for these amyloid-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.